Madrigal Pharmaceuticals has delivered very strong long term share price gains, yet the current valuation checks still lean toward the stock looking cheap on the broader scorecard. That combination raises questions for investors trying to judge whether recent trading levels already reflect the progress in the business.

• Over the past 5 years, Madrigal Pharmaceuticals has produced a very large total return, which puts extra focus on whether today’s price still leaves room for further value creation.
• Future revenue growth from its core drug franchise can support the current share price, while ongoing development and regulatory risks may limit how much investors are willing to pay ahead of clearer cash flow visibility.
• The broader checks lean cheap, with Madrigal Pharmaceuticals screening as undervalued on most measures, and the high value score 5 reflecting that overall read.

For investors, the debate is whether Madrigal Pharmaceuticals’ strong long term share price performance and sharp recent moves already capture its potential, or whether the current valuation still leaves a margin of safety.

Seize the chance to compare Madrigal Pharmaceuticals with other stocks that screen as undervalued on quality checks by reviewing the 46 high quality undervalued stocks.

Does Madrigal Pharmaceuticals Look Undervalued on Sales?

The P/S multiple is a useful way to look at Madrigal Pharmaceuticals because the focus is on revenue potential rather than current earnings.

Madrigal Pharmaceuticals currently trades on a P/S of 9.8x. This sits below the biotech industry average of 12.9x and also below the peer group average of 29.5x. On this framework, the stock is priced at a discount to many other listed biotechs when you compare market value to current sales.

A tailored fair P/S ratio for Madrigal Pharmaceuticals sits at 15.1x, which is higher than the current 9.8x level. That difference indicates the market is not fully reflecting the revenue profile implied by this model, even after the strong share price performance highlighted earlier.

On the P/S multiple, Madrigal Pharmaceuticals stock appears undervalued relative to both sector norms and its modelled fair ratio.

The Madrigal Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Madrigal Pharmaceuticals' valuation puzzle leaves off by spelling out which growth, margin and earnings assumptions would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each Narrative sets out a fair value as a thesis about Madrigal Pharmaceuticals' business that you can track over time and see how well the underlying assumptions hold up.

One of the top community narratives on Madrigal Pharmaceuticals: 20% undervalued

"Upcoming international expansion, beginning with the imminent launch in Germany and broader EU approval, positions the company to tap into new, underpenetrated markets..."

Do you think there's more to the story for Madrigal Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Madrigal Pharmaceuticals screens as undervalued on its P/S multiple, even after a very large 5 year return and recent sharp share price moves. That mix of a strong value tilt and volatile trading suggests the market is still debating how durable future revenue from its drug franchise will be and how much risk to assign to ongoing development and regulatory hurdles. For you, the key question is whether that current discount reflects caution on the revenue outlook that may be misplaced, or a buffer that fairly reflects the execution risks that still sit between today’s sales base and the more optimistic scenarios.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.